Lipid‐lowering drugs and serum liver enzymes: the effects of body weight and baseline enzyme levels

Abstract

The most important side effects of fibrate and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin) treatment are hepatic toxicity and myopathy. Obese individuals may have higher levels of serum transaminases than their lean counterparts. The main purpose of this study was to examine the effects of statins and fibrates on liver enzymes in obese patients and to compare them with their effects on patients with various body mass indexes (BMI). Two hundred and sixty-three hyperlipidemic patients of both sexes aged 31-74 years were studied for 24 weeks. One hundred and three patients received fluvastatin (40 mg/day), 62 atorvastatin (10-20 mg/day), 45 micronized fenofibrate (200 mg/day), 44 ciprofibrate (100 mg/day) and nine patients received gemfibrozil (900 mg/day). Laboratory determinations were performed at baseline, after 8 weeks of treatment and at the end of the follow-up period. At baseline, obese patients tended to exhibit elevated liver enzymes more frequently than their lean counterparts (12 of 105 vs. 5 of 67). At the end of the study period, 11 obese, seven overweight and six lean subjects exhibited elevated liver enzymes. Twelve patients who experienced a moderate elevation of serum liver enzymes at baseline had their liver enzyme profile normalized at the end of the study. Furthermore, in 12 patients who had normal serum liver enzyme levels at baseline, abnormal levels of at least one enzyme were observed after 24 weeks of treatment. Fibrates and statins are safe drugs for the treatment of hyperlipidemia in obese patients as well as in those with moderately increased liver enzymes.

Effects of a 6‐month infliximab treatment on plasma levels of leptin and adiponectin in patients with rheumatoid arthritis

“…All laboratory determinations were carried out after overnight fast using techniques previously described [15]. Low‐density lipoprotein cholesterol (LDL‐C) was calculated using the Friedewald formula (provided that triglycerides were <3.9 mmol/L, 350 mg/dL).…”

Alteration of Hepatic but Not Renal Transporter Expression in Diet-Induced Obese Mice

“…Disposition of vancomycin was also studied in obese and lean patients (Vance-Bryan et al, 1993). Last, antihyperlipidemic therapy by atorvastatin (ATV) was found to increase serum alanine aminotransferase levels more in obese than in lean patients, indicating a possibility for ATV-mediated liver injury (Kiortsis et al, 2003). Multiple transporters are involved in disposition of ATV, including FIG.…”

Efeitos da sinvastatina na hipertrofia lipídica da medula óssea induzida pelo uso de corticóides em ratos

“…Embora nas doses comumente empregadas as estatinas não provoquem lesão hepática significativa (35) , doses muito elevadas estão associadas ao desenvolvimento de necrose hepatocelular em animais de laboratório (36)(37)(38) . A manifestação hepática mais comum relacionada ao uso de estatinas é a elevação assintomática das transaminases (39)(40) .…”